TXG vs. VNT, ST, MIR, CAMT, TRNS, CTKB, EYPT, LAB, SENS, and ALNT
Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Vontier (VNT), Sensata Technologies (ST), Mirion Technologies (MIR), Camtek (CAMT), Transcat (TRNS), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Senseonics (SENS), and Allient (ALNT). These companies are all part of the "measuring and control equipment" industry.
10x Genomics vs.
10x Genomics (NASDAQ:TXG) and Vontier (NYSE:VNT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 95.8% of Vontier shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by insiders. Comparatively, 0.8% of Vontier shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
10x Genomics currently has a consensus price target of $20.21, indicating a potential upside of 107.33%. Vontier has a consensus price target of $44.67, indicating a potential upside of 30.30%. Given 10x Genomics' higher possible upside, analysts clearly believe 10x Genomics is more favorable than Vontier.
10x Genomics received 17 more outperform votes than Vontier when rated by MarketBeat users. However, 51.76% of users gave Vontier an outperform vote while only 51.26% of users gave 10x Genomics an outperform vote.
10x Genomics has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Vontier has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
Vontier has a net margin of 14.17% compared to 10x Genomics' net margin of -29.90%. Vontier's return on equity of 43.22% beat 10x Genomics' return on equity.
In the previous week, 10x Genomics had 8 more articles in the media than Vontier. MarketBeat recorded 12 mentions for 10x Genomics and 4 mentions for Vontier. Vontier's average media sentiment score of 1.43 beat 10x Genomics' score of 1.02 indicating that Vontier is being referred to more favorably in the news media.
Vontier has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Vontier, indicating that it is currently the more affordable of the two stocks.
Summary
Vontier beats 10x Genomics on 11 of the 18 factors compared between the two stocks.
Get 10x Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
10x Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:TXG) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy TXG Stock Free TXG Stock Alerts